NxStage Medical (NSDQ:NXTM) launched a new patient outreach program called NxStage Plus One, through which it hopes to increase awareness of home hemodialysis with the NxStage System One.
NxStage Medical Inc.
NxStage Medical’s Q4 prelims beat its own, Wall Street’s forecasts
NxStage Medical (NSDQ:NXTM) saw its stock price climb this morning after reporting preliminary 4th-quarter sales numbers that topped its own forecast and handily beat expectations on Wall Street.
NxStage, Fresenius extend System One deal
Fresenius (NYSE:FMS) and NxStage Medical (NSDQ:NXTM) said they extended a supply deal for NxStage’s System One hemodialysis device until 2016.
NxStage, Gambro bury the hatchet, renew supply deal
NxStage Medical gains on Medicare boost
NxStage Medical (NSDQ:NXTM) shares are on the rise this morning after the Centers for Medicare & Medicaid Services announced Friday that it will boost the training rate for home hemodialysis.
NXTM shares were trading at $9.98 apiece as of about 10 a.m. today, up 3.5%.
NxStage debuts 3 new home-dialysis products
NxStage Medical (NSDQ:NXTM) debuted 3 new products this week during the American Society of Nephrology’s Annual Kidney Week 2013.
The Lawrence, Mass-based medical device company trotted out its System One S, the next generation of NxStage’s System One. It features higher dialysate flow rates, allowing for a wider range of flexible therapy options.
Listen to NxStage Medical’s Q3 2013 earnings call
NxStage tanks on lowered 2013 guidance amid weak home hemo results
NxStage debuts 1st dialysis center
NxStage Medical (NSDQ:NXTM) said its NxStage Kidney Care division opened its 1st dialysis center outside of St. Louis after winning Medicare certification from the Missouri Board of Health.
NxStage Medical urges Medicare to pony up for home hemodialysis
Home hemodialysis system maker NxStage Medical (NSDQ:NXTM) urged the Centers for Medicare & Medicaid Services to increase coverage for home hemodialysis training for patients with end-stage renal disease.
NxStage Medical pares losses and boosts sales, but still takes a hit on Wall Street
NxStage Medical (NSDQ:NXTM) beat the Street’s earnings-per-share estimate by 1 penny and reported an 11% bump in sales, but it wasn’t enough to stop shares from sliding 4% this morning.